Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease
- 1 February 2013
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 60, 285-294
Abstract
No abstract availableKeywords
Funding Information
- Alzheimer's Drug Discovery Foundation
- NIH-NIA (U01-AG032973)
This publication has 40 references indexed in Scilit:
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developmentsBritish Journal of Pharmacology, 2012
- Phoshphodiesterase-5 Inhibitors: Novel Weapons Against Alzheimer's Disease?International Journal of Neuroscience, 2010
- Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behaviorBehavioural Brain Research, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- β-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or β-amyloid depositsProceedings of the National Academy of Sciences, 2006
- Amyloid-β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic PlasticityJournal of Neuroscience, 2005
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- Tissue expression, distribution, and regulation of PDE5International Journal Of Impotence Research, 2004
- Substituted Pyrazolopyridopyridazines as Orally Bioavailable Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile DysfunctionJournal of Medicinal Chemistry, 2003
- Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivoNature, 2002